Motif Bio Share Discussion Threads

[barriew] 14/12/2018 15:37

R-i-T-A

Normally for a FDA application there is a charge, I think several million was quoted once but motif had a free application I can’t remember if it was unmet need, or with the SPA.
Perhaps this is not the case with a EMA- perhaps they wanted to save money get the fda approval first, a deal agreed before risking more money on this.
Just my thoughts.
Anyway the main thing at the moment is the FDA and Xmas will fly past, then it’s not long to wait, keep positive folks.

[adorling] 14/12/2018 10:31

Just added another 20,000 at 25.355p - just cannot ignore this low price when we are only 8 weeks away from FDA decision and the World needs new antibiotics urgently. Definitely risk reward in our favour IMO.

[return_of_the_apeman] 14/12/2018 09:10

Barriew,

They have not stateted that. What they have said is in the final accounts they talk about submitting to both the FDA and EMA 'during 2018'.

With a only a few working days left now in 2018 and since they were late on the FDA submission, this looks like a miss.

Wtf have they been upto for 6 months except burning my cash?

I feel another email to the company coming on, doubt I will get anthing useful back but atleast I will feel better having vented off at them

[catch007] 12/12/2018 16:24

13th Feb isn't that far away....we are certain to see speculators joining the thread with all sorts of ramping noise in the coming weeks however if FDA approves we will see a hockey stick rise in share price

[barriew] 11/12/2018 16:36

They may be waiting for FDA approval then If someone wants to buy world wide distribution rights they with put in for EMA submission,

[return_of_the_apeman] 11/12/2018 09:27

Where is the EMA submission, how can it take more than 6 months following the FDA submission?

I know it's not a cut and paste excersise, but come on 6 months ffs

[barriew] 08/12/2018 10:40

Mike they should rise before the FDA decision before the 13th February.
No one can guess share prices but it’s looking cheap at the moment.

[barriew] 08/12/2018 10:40

Mike they should rise before the FDA decision before the 13th February.
No one can guess share prices but it’s looking cheap at the moment.

[1fraser] 07/12/2018 23:25

Na let them grow

[catch007] 07/12/2018 14:08

I bought some at 40p & 32p mike1608 but it has always been a speculative hold. The share price is just marked down on the market falls in an unsupported limbo position until we gain outcomes in spring 2019. I felt the evidential work within the submission was conducted diligently and keep the faith. If it gets approval we will see a substantial share price spike if not it will become another summit/IMM. GL whatever you decide

[mike1608] 07/12/2018 12:40

I bought shares of an average of 30p per share. Should I cut loses?

[barriew] 06/12/2018 13:40

Everything is down regardless, just vrs having a good day for me.
Not long until February

[l4z4rus] 06/12/2018 12:30

Time to accumulate!

[barriew] 03/12/2018 12:14

It’s a waiting game, the hard part was getting the trials finished and the great results , within 10% of vancomycin.
Now it’s just hold your nerve until the FDA report. Some would rather cut losses and invest elsewhere, other will accumulate.
Others will try and talk the price down and run a short position.
Everyone to their own.

To me everything is positive at the moment, upon FDA acceptance or refusal we can only sit and wait. It’s not like imm which was talked up by the board and this BB only to crash from a badly run trial.

[bountyhunter] 28/11/2018 12:55

Agreed, with small caps charting is of very limited use. The price will be driven by newsflow and fundamentals in the medium to long term.

[rabito79] 28/11/2018 10:32

The price was lower than this last year. Furthermore I would believe most here will be investing on fundamentals opposed to technicals. Whilst its frustrating for the price to drop below recent support I don't believe this has any implications regards the fundamentals as previously alluded.

[uncleoswald] 28/11/2018 09:08

Price dropped below 28 for the first time.
Sold out.
Let the trend be your friend.
Good luck to those holding.

[catch007] 27/11/2018 18:09

Investors get nervous when there is no news flow. Add to this recent examples of Summit & IMM and many others the risk of failure and losses takes hold. I lost heavily on IMM however I do believe the MTFB has carefully delivered what it said it would throughout this approval process and has been meticulous in data collection, analysis, presentation and into formal submission. The company has provided due dates for outcomes and given the volume of data it would be highly unlikely to get indicative response at this juncture. Global indices have all shown significant weakness and the MTFB share price has also fallen back significantly. I am a holder rather than a buyer at present however it remains highly speculative I wholly agree with gclark and I believe (and hope) the data is vindicated with an approval.

[gclark] 27/11/2018 09:23

Maybe. I have looked at the volume and it is pretty low. Investors may want the money for what they regard is a better short term prospect. I have sold some mtfb and amphion in the past for that reason.
But I've just bought a little more mtfb.
The clinical evidence looks good to me.
I was wrong about summit but that was about an ongoing clinical trial which has a lot of unknowns. In this case the data is there.
But everything is a risk!

[uncleoswald] 27/11/2018 08:12

The share graph does not look good.
With 3 months to go til approval by the FDA for a new antibiotic, you would expect the share price to be hitting new highs.
Instead, it is hitting new lows.
Conclusion you have to draw is someone knows it is not going to get approval.
Can’t think of any other logical reason.
If that is the case, price will continue dropping!

[philoosh] 26/11/2018 16:12

Why is this going down further?

[hoggar] 20/11/2018 13:50

Thought they would have lined up a distribution partner by now or at least a short list of contenders. If Motif have hired Ms May to negotiate this deal, then investors will have to endure a double stab in the back?

[philoosh] 20/11/2018 12:56

Even more nervously now......

[spmc] 09/11/2018 14:59

For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.